Evidence map›Paper›PMID 23901236›Full record

ArticleWorld journal of gastroenterology2013

Antinociceptive effect of berberine on visceral hypersensitivity in rats.

Qing-Lin Tang, Min-Ling Lai, Yuan-Fu Zhong, Ai-Min Wang, Jun-Kai Su, Ming-Qing Zhang

Open access · hybridAbstract read
In one paragraph

Article in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 56 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Fibrauretine reduces ischemia/reperfusion injury via RISK/eNOS activation.Naunyn-Schmiedeberg's archives of pharmacology · 2020
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Berberine protects vascular endothelial cells in hypertensive rats.International journal of clinical and experimental medicine · 2015
    Article
  14. Berberine, an epiphany against cancer.Molecules (Basel, Switzerland) · 2014
    Review
  15. Changes in mast cell infiltration: a possible mechanism in detrusor overactivity induced by visceral hypersensitivity.International braz j urol : official journal of the Brazilian Society of Urology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Qing-Lin TangDepartment of Gastroenterology, 175 Hospital of PLA, Affiliated Southeast Hospital of Xiamen University, Zhangzhou 363000, Fujian Province, China.
Min-Ling Lai
Yuan-Fu Zhong
Ai-Min Wang
Jun-Kai Su
Ming-Qing Zhang
Zhangzhou Municipal Hospital of Fujian Province · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo assess the protective effect of berberine administration and the role of nitric oxide (NO) in visceral hypersensitivity.

methodsFifty male Sprague-Dawley rats were randomly assigned to five groups. An inflammatory bowel disease model was induced in rats by intracolonic instillation of 1 mL 4% acetic acid at 8 cm proximal to the anus for 30 s and restraint stress. After subsidence of inflammation on day 7 of the experiment, the rats were subjected to rectal distension, performed by a balloon (6-Fr, 2 mm external diameter, disposable silicon balloon-urethral catheter for pediatric use) which was rapidly inflated with increasing volumes of prewarmed (37 °C) water (0.1, 0.2, 0.3, 0.4, 0.6, 0.8 and 1 mL) for 30 s at four-minute intervals, and then the abdominal withdrawal reflex (AWR) and the level of fecal output were measured, respectively. AWR scores either 0, 1, 2, 3 or 4 were obtained by blinded observers. Rats had been pretreated with berberine or aminoguanidine (NO synthetase inhibitor) or berberine + aminoguanidine before measurement.

resultsThe rats in the placebo group showed a hypersensitive response to rectal distension (2.69 ± 0.08 vs 1.52 ± 0.08, P = 0.000) and defecated more frequently than those in the control group (5.0 ± 0.16 vs 0.44 ± 0.16, P = 0.000). Comparing the berberine with placebo group, the AWR scores were reduced for all distension volumes and were significant at 0.2-1 mL (1.90 ± 0.08 vs 2.69 ± 0.08, P = 0.000), while the numbers of hard pellets, soft pellets, formless stools, and total fecal output in the placebo group were significantly larger than in the berberine group (5.0 ± 0.16 vs 2.56 ± 0.16, P = 0.000). Administration of aminoguanidine or berberine + aminoguanidine before VH score measurement reversed the antinociceptive effect of berberine (2.52 ± 0.08 vs 1.90 ± 0.08, P = 0.000; 2.50 ± 0.08 vs 1.90 ± 0.08, P = 0.000). The numbers of hard pellets, soft pellets, formless stool, and total of fecal output in aminoguanidine group were significantly larger than the corresponding values in control group, berberine group, and berberine + aminoguanidine group (4.81 ± 0.16 vs 0.44 ± 0.16, P = 0.000; 4.81 ± 0.16 vs 2.56 ± 0.16, P = 0.000; 4.81 ± 0.16 vs 3.75 ± 0.16, P = 0.000). The berberine and berberine + aminoguanidine groups showed reduced defecation, but aminoguanidine alone did not reduce defecation (2.56 ± 0.16 vs 4.81 ± 0.16, P = 0.000; 3.75 ± 0.16 vs 4.81 ± 0.16, P = 0.000).

conclusionBerberine had an antinociceptive effect on visceral hypersensitivity, and NO might play a role in this effect.

Indexed as

Acetic AcidAnalgesicsAnimalsBerberineColonDefecationDisease Models, AnimalDisease ProgressionHyperalgesiaInflammatory Bowel DiseasesMaleMechanotransduction, CellularNitric OxideNociceptionPressureRatsAcetic AcidAnalgesicsBerberineNitric OxideBerberineIrritable bowel syndromeNitric oxideVisceral hypersensitivity

Identifiers

PMID23901236
PMCPMC3725385
OpenAlexW2084501476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.